[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053529":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":38,"responsibleParty":93,"collaborators":28,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":28,"enrollmentInfo":105,"targetDuration":28,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":28,"overallStatus":114,"whyStopped":28,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy 2L\u002F3L","EXPERIMENTAL","2L\u002F3L VS-7375 dose",[13],"Drug: VS-7375",{"label":15,"type":10,"description":16,"interventionNames":17},"VS-7375 Monotherapy 2L\u002F3L Preferred Dose","2L\u002F3L Preferred VS-7375 dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"2L-4L with brain metastasis","2L-4L VS-7375 dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","VS-7375","Taken by mouth",[19,9,15],null,[30,35],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Verastem Call Center","CONTACT","7812924204","VS-7375-202TrialSupport@verastem.com",{"name":36,"role":32,"phone":28,"phoneExt":28,"email":37},"Ting Wu, MD","VS-7375-202Medical@verastem.com",[39,60,77],{"facility":40,"status":28,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"START LA","Los Angeles","California","90025","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-118.24368,34.05223,{"lat":50,"lon":49},[53,57],{"name":54,"role":32,"phone":55,"phoneExt":28,"email":56},"Hope Team Distribution List","4244651820","hopeteam@startresearch.com",{"name":58,"role":59,"phone":28,"phoneExt":28,"email":28},"Navid Hafez, MD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":28,"city":62,"state":63,"zip":64,"country":44,"countryCode":45,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"START New Jersey","East Brunswick","New Jersey","08816",{"type":47,"coordinates":66},[67,68],-74.41598,40.42788,{"lat":68,"lon":67},[71,75],{"name":72,"role":32,"phone":73,"phoneExt":28,"email":74},"Emily Lichtenstein","7324264750","emily.lichtenstein@startresearch.com",{"name":76,"role":59,"phone":28,"phoneExt":28,"email":28},"Bruno Fang, MD",{"facility":78,"status":28,"city":79,"state":80,"zip":81,"country":44,"countryCode":45,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"START Fort Worth","Fort Worth","Texas","76104",{"type":47,"coordinates":83},[84,85],-97.32085,32.72541,{"lat":85,"lon":84},[88,91],{"name":89,"role":32,"phone":90,"phoneExt":28,"email":56},"Hope Team","6823503010",{"name":92,"role":59,"phone":28,"phoneExt":28,"email":28},"Salwan Almutar, MD",{"type":94,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100053529","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-non-small-cell-lung-cancer-100053529",false,"NCT07659782","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)","TARGET-D 202","Inclusion Criteria:\n\n* Histopathology confirmed unresectable locally advanced or metastatic NSCLC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n* Adequate organ function\n* Received prior treatment with a platinum-based chemotherapy regimen and an immune checkpoint inhibitor in the advanced, non-resectable setting.\n* Have documented disease progression during or following their most recent prior line of therapy.\n\nPatients with 2L\u002F3L on stable or preferred dose:\n\n* Received at least 1 and no more than 2 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n\nPatients with 2L-4L with brain metastases:\n\n* Received at least 1 and no more than 3 prior systemic lines of therapy for advanced (in the unresectable locally advanced or metastatic setting) NSCLC.\n* Have asymptomatic and untreated brain metastases\n* At least 1 untreated measurable brain lesion per mRECIST v1.1 with a long axis ≥ 0.5 cm and ≤ 3 cm.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* History of drug-induced Interstitial Lung Disease\n* Receipt of prior direct RAS inhibitor\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":106,"type":107},105,"ESTIMATED","INTERVENTIONAL",[110],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer",[113],"Non-Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-07-09",{"date":117,"type":118},"2026-07-13","ACTUAL",{"date":120,"type":107},"2026-06",{"date":122,"type":107},"2028-12",{"name":5,"class":6},3]